Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
Research Site, Mölndal, Sweden
Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain
Hospital Clinic of Barcelona, Barcelona, Catalonia, Spain
Research Site, Xian, China
Hospital Clínico Universitario de Valencia, Valencia, Spain
October 6 University Hospital, Giza, Egypt
King's College Hospital, London, United Kingdom
Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, China
National Taiwan University Hospital, Taipei, Taiwan
Karmanos Cancer Institute, Detroit, Michigan, United States
Peking University People's Hospital, Beijing, China
Binzhou Medical University Hospital, Binzhou, China
The Second Norman Bethune Hospital of Jilin University, Changchun, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.